Life, Journal Year: 2025, Volume and Issue: 15(3), P. 403 - 403
Published: March 4, 2025
During the coronavirus disease 2019 (COVID-19) pandemic, several studies highlighted a worse prognosis for patients with alterations in liver function tests, especially those pre-existing diseases. However, further are needed to define long-term impact of COVID-19 pandemic on Long encompasses wide range signs and symptoms, including exacerbations chronic conditions or new onset developed after acute phase. Therefore, effects extensively include hepatic manifestations. The co-expression angiotensin-converting receptor 2 (ACE2) transmembrane serine protease (TMPRSS2) has been demonstrated also enterocytes, cholangiocytes, hepatocytes. Studies post-COVID-19 sequelae have shown presence steatosis necroinflammation liver, concomitantly an alteration inflammation, cytolysis cholestasis indices. Some increased risk hepatobiliary pathologies, secondary biliary cholangitis worsening severity metabolic-associated fatty (MASLD). Based these premises, this review aims provide overview pathophysiological mechanisms contributing COVID-19-related damage; explore its implications inflammation fibrosis, particular focus MASLD metabolic dysfunction-associated steatohepatitis (MASH); analyze short- sequelae. A literature search was conducted using PubMed database relevant published English.
Language: Английский